Brevera Breast Biopsy System from Hologic Inc. - real-time tissue imaging at the bedside

Reviewed: ad hoc news B2B & Pro desk. Edited and checked on 2026-06-27, 07:59. Details in the imprint.

Brevera Breast Biopsy System from Hologic sits in a dimmed procedure room, the monitor glowing while fresh tissue cores slide into view within seconds. The technologist hears the quiet vacuum hum, the patient barely shifts, and the radiologist sees instantly whether the sample looks sufficient.

How Brevera changes the biopsy

The Brevera Breast Biopsy System combines a vacuum-assisted needle with an integrated imaging unit, so the tissue sample is imaged in real time instead of being rushed to a separate cabinet. That cuts the pause between taking a core and checking it down to mere seconds in practice.

Hologic positions Brevera for stereotactic and tomosynthesis-guided biopsies, streamlining the workflow around its 3D mammography platforms rather than leaving staff to shuttle cartridges between rooms. Radiologists like Dr. Jennifer Meier in US breast centers describe it as a calmer, more controlled experience for anxious patients.

Tactile workflow in the procedure room

At the table, the clinician feels a solid, slightly rubberized handpiece rather than a bare metal tube, which helps when gloved fingers get damp during longer procedures. The needle advance is clearly audible but not harsh, more of a firm click than a jarring snap.

Once the vacuum draws tissue into the chamber, the system pulls the core into a sealed cassette that slides with a smooth, mechanical motion toward the imaging section inside the console. The nurse no longer has to walk across the room holding an open specimen pot while the patient lies waiting.

Real-time imaging and time savings

The key promise of Brevera is to shave minutes off every biopsy by combining tissue acquisition, imaging and automated vacuum transport in one console. In busy breast centers that sum can turn into extra appointment slots per day and shorter waiting lists.

Because the radiologist can decide on the spot whether to take more cores, there are fewer repeat procedures caused by inadequate sampling. That reduces stress for patients and frees capacity for hospitals under pressure to screen more women earlier.

Where the system still demands discipline

Brevera is very much a professional tool: staff need training on both the software interface and the specific cartridge handling before the promised efficiency gains show up in daily practice. Without that, the sleek console can quickly turn into an expensive bottleneck.

The system also depends on reliable integration with existing imaging platforms and picture archiving, so IT teams have to align protocols and user rights carefully. That is extra upfront work for clinics that have grown their systems piece by piece over many years.

Hologic and the stock perspective

Hologic built Brevera into its broader ecosystem of breast health products, from 3D mammography to biopsy markers, as CEO Stephen P. MacMillan repeatedly frames the company as a full-pathway partner for women’s diagnostics. For investors, Hologic shares (ISIN US4364401012) continue to trade on the Nasdaq in US dollars, with biopsy platforms contributing to the recurring equipment and consumables mix.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.

en | US4364401012 | HOLOGIC | boerse | 69637448 | bgmi